» Articles » PMID: 39467697

Unlocking Cardioprotective Potential of Gut Microbiome: Exploring Therapeutic Strategies

Overview
Date 2024 Oct 28
PMID 39467697
Authors
Affiliations
Soon will be listed here.
Abstract

The microbial community inhabiting the human gut resembles a bustling metropolis, wherein beneficial bacteria play pivotal roles in regulating our bodily functions. These microorganisms adeptly break down resilient dietary fibers to fuel our energy, synthesize essential vitamins crucial for our well-being, and maintain the delicate balance of our immune system. Recent research indicates a potential correlation between alterations in the composition and activities of these gut microbes and the development of coronary artery disease (CAD). Consequently, scientists are delving into the intriguing realm of manipulating these gut inhabitants to potentially mitigate disease risks. Various promising strategies have emerged in this endeavor. Studies have evidenced that probiotics can mitigate inflammation and enhance the endothelial health of our blood vessels. Notably, strains such as Lactobacilli and Bifidobacteria have garnered substantial attention in both laboratory settings and clinical trials. Conversely, prebiotics exhibit anti-inflammatory properties and hold potential in managing conditions like hypertension and hypercholesterolemia. Synbiotics, which synergistically combine probiotics and prebiotics, show promise in regulating glucose metabolism and abnormal lipid profiles. However, uncertainties persist regarding postbiotics, while antibiotics are deemed unsuitable due to their potential adverse effects. On the other hand, TMAO blockers, such as 3,3-dimethyl-1-butanol, demonstrate encouraging outcomes in laboratory experiments owing to their anti-inflammatory and tissue-protective properties. Moreover, fecal transplantation, despite yielding mixed results, warrants further exploration and refinement. In this comprehensive review, we delve into the intricate interplay between the gut microbiota and CAD, shedding light on the multifaceted approaches researchers are employing to leverage this understanding for therapeutic advancements.

Citing Articles

Exo- and Endo-1,5-α-L-Arabinanases and Prebiotic Arabino-Oligosaccharides Production.

Ju Y, Im S, Jung D, Son M, Park C, Jeon M J Microbiol Biotechnol. 2025; 35:e2412052.

PMID: 39849927 PMC: 11813348. DOI: 10.4014/jmb.2412.12052.

References
1.
Pham V, Dold S, Rehman A, Bird J, Steinert R . Vitamins, the gut microbiome and gastrointestinal health in humans. Nutr Res. 2021; 95:35-53. DOI: 10.1016/j.nutres.2021.09.001. View

2.
Roberts A, Gu X, Buffa J, Hurd A, Wang Z, Zhu W . Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med. 2018; 24(9):1407-1417. PMC: 6129214. DOI: 10.1038/s41591-018-0128-1. View

3.
Kendrick S, OBoyle G, Mann J, Zeybel M, Palmer J, Jones D . Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology. 2010; 51(6):1988-97. DOI: 10.1002/hep.23572. View

4.
Hasan A, Rahman A, Kobori H . Interactions between Host PPARs and Gut Microbiota in Health and Disease. Int J Mol Sci. 2019; 20(2). PMC: 6359605. DOI: 10.3390/ijms20020387. View

5.
Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L . A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2016; 23(1):107-113. DOI: 10.1038/nm.4236. View